Panacea Biotec, THSTI tie up to make broad Covid vax, trials in 15-18 mths

If things go according to plan this India-made vaccine could hit the market within the next two to three years

Panacea Biotec along with public sector institute Translational Health Science and Technology Institute (THSTI) have begun work on developing a coronavirus vaccine that would offer ‘broad protection’ against not only the Sars-CoV-2 virus, but also its cousins - Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The idea is to develop a pre-emptive vaccine for future coronavirus outbreaks.

If things go according to plan this India-made vaccine could be available to the public in the next two to three years.

Global vaccine body CEPI (the Coalition for Epidemic Preparedness Innovations) has already announced an award to develop